NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12
Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image oligonucleotides. Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not hybridize with native nucleic acids. Spiegelmers® also do not activate the innate immune response via Toll-like receptors and have shown an exceptionally favorable immunogenicity profile in pre-clinical testing. The phase I clinical development of NOX-A12 will follow closely behind that of NOXXON's lead candidate NOX-E36, which entered human testing in June of 2009.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.